Esperion Therapeutics, Inc.
看多
已更新

$ESPR - Long Esperion Therapeutics

110
Potential long.

Reported solid phase 1 and phase 2 results for its drug Bempedoic Acid.

Amgen is soon releasing results from a similar drug; if results are promising, ESPR could trend up.

Also forming cup and handle pattern.
註釋
Watch for the break over $12.00
註釋
DISCLAIMERS:
**The trades seen in this post are in no way intended to be used as advice or guidance for your own trading. These posts are intended for an educational and entertainment purpose only. Day trading and investing in the stock market in general is high risk. Please do not take any comments as direction in trading your own account, and as such, I will not be held liable by any financial losses in your account. **

**I am not a financial advisor. The ideas presented in this post are personal opinions and for entertainment purposes only.**

免責聲明

這些資訊和出版物並不意味著也不構成TradingView提供或認可的金融、投資、交易或其他類型的意見或建議。請在使用條款閱讀更多資訊。